146 related articles for article (PubMed ID: 35166222)
1. Yttrium-90 (Y-90) resin microsphere therapy for patients with unresectable hepatocellular carcinoma. Identification of successful treatment response predictors and patient selection.
Arslan N; Ince S; Okuyucu K; San H; Alagoz E; Karadurmus N; Karaman B; Ercin CN
Ann Ital Chir; 2021; 92():623-631. PubMed ID: 35166222
[TBL] [Abstract][Full Text] [Related]
2. Yttrium-90 (Y-90) Resin Microsphere Therapy for Patients with Unresectable Hepatocellular Carcinoma: a Single-Center Experience.
İnce S; Karaman B; Alagoz E; Karadurmuş N; Şan H; Erçin CN; Arslan N
J Gastrointest Cancer; 2017 Sep; 48(3):281. PubMed ID: 28634669
[TBL] [Abstract][Full Text] [Related]
3. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
5. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors.
Kucuk ON; Soydal C; Lacin S; Ozkan E; Bilgic S
World J Surg Oncol; 2011 Aug; 9():86. PubMed ID: 21819613
[TBL] [Abstract][Full Text] [Related]
6. Selective internal radiation therapy with yttrium-90 resin microspheres followed by anatomical hepatectomy: A potential curative strategy in advanced hepatocellular carcinoma.
Feng X; Zhang L; Niu H; Zhang H; Yang L; Wen Y; Chen SY; Shi Y; He Z; Yu L; Wang Y; Huang X; Wang Z; Qin M; Wen X; Zhang Z; Song J; Zheng Z; Yin H; Zhang H; Ma L; Wei J; Wu X; Zhang L; Zhao Y; Lu Q; Xiao H; Liu T; Fang P; Wei L; Gandhi RT; Dong J
Asia Pac J Clin Oncol; 2024 Apr; 20(2):319-322. PubMed ID: 36658669
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma.
Van Thai N; Thinh NT; Ky TD; Bang MH; Giang DT; Ha LN; Son MH; Tien DD; Lee HW
BMC Gastroenterol; 2021 May; 21(1):216. PubMed ID: 33980171
[TBL] [Abstract][Full Text] [Related]
8. A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK.
Pollock RF; Colaone F; Guardiola L; Shergill S; Brennan VK
J Med Econ; 2020 Jun; 23(6):593-602. PubMed ID: 32067534
[No Abstract] [Full Text] [Related]
9. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman O; Elsayed Z
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011313. PubMed ID: 31978267
[TBL] [Abstract][Full Text] [Related]
10. Current role of selective internal irradiation with yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review.
Lau WY; Lai EC; Leung TW
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):460-7. PubMed ID: 20888138
[TBL] [Abstract][Full Text] [Related]
11. Resin Versus Glass Microspheres for
Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
[TBL] [Abstract][Full Text] [Related]
12. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis.
Tsai AL; Burke CT; Kennedy AS; Moore DT; Mauro MA; Dixon RD; Stavas JM; Bernard SA; Khandani AH; O'Neil BH
J Vasc Interv Radiol; 2010 Sep; 21(9):1377-84. PubMed ID: 20691606
[TBL] [Abstract][Full Text] [Related]
13. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer.
Salem R; Thurston KG; Carr BI; Goin JE; Geschwind JF
J Vasc Interv Radiol; 2002 Sep; 13(9 Pt 2):S223-9. PubMed ID: 12354840
[TBL] [Abstract][Full Text] [Related]
14. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
Ricke J; Klümpen HJ; Amthauer H; Bargellini I; Bartenstein P; de Toni EN; Gasbarrini A; Pech M; Peck-Radosavljevic M; Popovič P; Rosmorduc O; Schott E; Seidensticker M; Verslype C; Sangro B; Malfertheiner P
J Hepatol; 2019 Dec; 71(6):1164-1174. PubMed ID: 31421157
[TBL] [Abstract][Full Text] [Related]
15. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
16. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radio-conjugates.
Keng GH; Sundram FX; Yu SW; Somanesan S; Premaraj J; Oon CJ; Kwok R; Htoo MM
Ann Acad Med Singap; 2002 May; 31(3):382-6. PubMed ID: 12061301
[TBL] [Abstract][Full Text] [Related]
17. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
[TBL] [Abstract][Full Text] [Related]
18. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and Predictors of Toxicity after Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres for Unresectable Hepatocellular Carcinoma.
Gabrielson A; Miller A; Banovac F; Kim A; He AR; Unger K
Front Oncol; 2015; 5():292. PubMed ID: 26779437
[TBL] [Abstract][Full Text] [Related]
20. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
